Overview of enzymes of drug metabolism

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 24, Issue 5, 1996, Pages 449-459

  Meyer, Urs A ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Cytochrome P450; Drug metabolism; Genetic polymorphism; In vitro prediction; Induction; Interindividual variation

Indexed keywords

CYTOCHROME P450; DEXAMETHASONE; GLUTETHIMIDE; PHENACETIN; PHENAZONE; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; UNSPECIFIC MONOOXYGENASE;

BIOTRANSFORMATION; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; IN VITRO STUDY; LIVER FUNCTION; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW;

BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; HUMANS; LIVER; MICROSOMES, LIVER; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; VARIATION (GENETICS);

EID: 0030426570     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02353473     Document Type: Review

References (21)

1. P. R. Ortiz de Montellano (ed.). Cytochrome P450. Structure, Mechanism, and Biochemistry, Plenum Press, New York, 1995.
2. M. Pirmohamed, N. R. Kitteringham, and B. K. Park. The role of active metabolites in drug toxicity. Drug Safety 11:114-144 (1994).
3. D. R. Nelson, T. Kamataki, D. J. Waxman, F. P. Guengerich, R. W. Estabrook, R. Feyereisen, F. J. Gonzalez, M. J. Coon, I. C. Gunsalus, O. Gotoh, K. Okuda, and D. W. Nebert. The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 12:1-51 (1993).
4. U. A. Meyer, R. C. Skoda, U. M. Zanger, M. Heim, and F. Broly. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms. In W. Kalow (ed.), Pharmacogenetics of Drug Metabolism, Pergamon, New York, 1992, pp. 609-623.
5. U. A. Meyer. Commentary. Pharmacogenetics: The slow, the rapid, and the ultrarapid. Proc. Natl. Acad. Sci. U.S. 91:1983-1984 (1994).
6. W. Kalow, H. W. Goedde, and D. P. Agarwal. Ethnic Differences in Reactions to Drugs and Xenobiotics, AR Liss, New York, 1986.
7. M. Heim and U. A. Meyer. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 336:529-532 (1990).
8. F. Broly, D. Marez, N. Sabbagh, M. Legrand, S. Millecamps, J.-M. Lo Guidice, P. Boone, and U. A. Meyer. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 5:373-384 (1995).
9. S. M. F. De Morais, G. R. Wilkinson, J. Blaisdell, K. Nakamura, U. A. Meyer, and J. A. Goldstein. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269:15419-15422 (1994).
10. S. M. F. De Morais, G. R. Wilkinson, J. Blaisdell, U. A. Meyer, K. Nakamura, and J. A. Goldstein. Identification of new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46:594-598 (1994).
11. U. A. Meyer and U. M. Zanger. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37: 269-296 (1997).
12. A. B. Okey. Enzyme induction in the cytochrome P450 system. In W. Kalow (ed.), Pharmacogenetics of Drug Metabolism, Pergamon, New York, 1992, pp. 549-608.
13. D. J. Waxman and L. Azaroff. Phenobarbital induction of cytochrome P450 gene expression. Biochem. J. 281:577-592 (1992).
14. J. P. Whitlock, Jr. Mechanistic aspects of dioxin action. Chem. Res. Toxicol. 6:754-763 (1993).
15. J. George, M. Murray, K. Byth, and G. C. Farrell. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 21:120-128 (1995).
16. P. J. Meier, H. K. Mueller, B. Dick, and U. A. Meyer. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gastroenterology 85:682-692 (1993).
17. T. Kronbach, V. Fischer, and U. A. Meyer. Cyclosporine metabolism in human liver: Identification of a cytochrome P450 of the P450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther. 43:630-635 (1988).
18. T. Kronbach, D. Mathys, M. Umeno, F. J. Gonzalez, and U. A. Meyer. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36:89-96 (1989).
19. T. Andersson, J. O. Miners, M. E. Veronese, W. Tassaneeyakul, W. Tassaneeyakul, U. A. Meyer, and D. J. Birkett. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol. 36:521-530 (1993).
20. F. P. Guengerich, D. Müller-Enoch, and I. A. Blair. Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol. 30:287-295 (1986).
21. R. Fonne-Pfister and U. A. Meyer. Xenobiotic and endobiotic inhibitors of cytochrome P450db1 function, the target of the debrisoquine/sparteine type polymorphism. Biochem. Pharmacol. 37:3829-3835 (1988).